Microbot Medical Ownership
| MBOT Stock | USD 1.73 0.19 9.90% |
Microbot Stock Ownership Analysis
About 14.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.72. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Microbot Medical recorded a loss per share of 0.45. The entity last dividend was issued on the 5th of September 2018. The firm had 1:15 split on the 5th of September 2018. Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Microbot Medical Inc. was founded in 2010 and is based in Hingham, Massachusetts. Microbot Medical operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 20 people. To find out more about Microbot Medical contact Harel Gadot at 781 875 3605 or learn more at https://microbotmedical.com.Microbot Medical Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Microbot Medical insiders, such as employees or executives, is commonly permitted as long as it does not rely on Microbot Medical's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Microbot Medical insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Microbot Medical Outstanding Bonds
Microbot Medical issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Microbot Medical uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Microbot bonds can be classified according to their maturity, which is the date when Microbot Medical has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Microbot Stock Analysis
When running Microbot Medical's price analysis, check to measure Microbot Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Microbot Medical is operating at the current time. Most of Microbot Medical's value examination focuses on studying past and present price action to predict the probability of Microbot Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Microbot Medical's price. Additionally, you may evaluate how the addition of Microbot Medical to your portfolios can decrease your overall portfolio volatility.